인터류킨 억제제 시장 : 유형별, 투여 경로별, 용도별, 유통 채널별, 지역별

Global Interleukin Inhibitors Market is estimated to be valued at USD 36.78 Bn in 2025 and is expected to reach USD 85.51 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.8% from 2025 to 2032.

Figure. Interleukin Inhibitors Market Share (%), By Region 2025

Interleukin inhibitors are biologics that block or dampen the activity of interleukin cytokines that play important roles in triggering inflammation. These proteins act as signaling molecules that are critical in directing the movement of white blood cells to sites of injury or infection. However, excess or prolonged inflammation can cause issues. Interleukin inhibitors help control conditions driven by inappropriate or excessive immune responses by targeting specific interleukins. Some key interleukin targets include IL-17, IL-23, and IL-1B that are implicated in autoimmune diseases. The global interleukin inhibitors market has been growing steadily as new biologics gain regulatory approvals for treating various inflammatory and immune-mediated disorders.

Market Dynamics:

The global interleukin inhibitors market is driven by the increasing prevalence of immune-mediated conditions worldwide coupled with rising healthcare expenditures. In November 2025, according to the WHO estimates, around 2-3% of the global population suffers from autoimmune diseases with many cases remaining undiagnosed or untreated. Approvals of novel interleukin inhibitors for treating diseases with high unmet needs such as psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis are also boosting the market growth. However, high costs of biologics pose a major challenge for market expansion in price-sensitive developing regions. Moreover, patent cliffs of blockbuster drugs further intensify competition. Nevertheless, ongoing R&D for developing interleukin inhibitors with improved safety profiles and new therapeutic indications provide attractive opportunities for market players.

Key Features of the Study:

This report provides in-depth analysis of the global interleukin inhibitors market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global interleukin inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include AbbVie Inc., Johnson & Johnson, Amgen Inc., Novartis AG, Sanofi S.A., GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., UCB S.A., Astellas Pharma Inc., Bayer AG, and Sandoz International GmbH

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global interleukin inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interleukin inhibitors market

Market Segmentation

• By Type Insights (Revenue, USD Bn, 2020 - 2032)
  • IL-1 inhibitors
  • IL-5 inhibitors
  • IL-6 inhibitors
  • IL-17 inhibitors
  • IL-23 inhibitors
  • Other types
• By Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Subcutaneous (SC)
  • Intravenous (IV)
  • Others
• By Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Psoriasis
  • Inflammatory bowel disease (IBD)
  • Asthma
  • Multiple Sclerosis
  • Ulcerative colitis
  • Crohn's disease
  • Other applications
• By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • AbbVie Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • Novartis AG
  • Sanofi S.A.
  • GSK plc
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen Inc.
  • UCB S.A.
  • Astellas Pharma Inc.
  • Bayer AG
  • Sandoz International GmbH

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Interleukin Inhibitors Market, By Type
  • Global Interleukin Inhibitors Market, By Route of Administration
  • Global Interleukin Inhibitors Market, By Application
  • Global Interleukin Inhibitors Market, By Distribution Channel
  • Global Interleukin Inhibitors Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Driver
  • Restraint
  • Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Interleukin Inhibitors Market, By Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• IL-1 inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• IL-5 inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• IL-6 inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• IL-17 inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• IL-23 inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Interleukin Inhibitors Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Subcutaneous (SC)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intravenous (IV)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Interleukin Inhibitors Market, By Application, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Rheumatoid arthritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Psoriatic arthritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Psoriasis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Inflammatory bowel disease (IBD)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Asthma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Multiple Sclerosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Ulcerative colitis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Crohn's disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other applications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Interleukin Inhibitors Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Interleukin Inhibitors Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive landscape

• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
• Amgen Inc.
• Novartis AG
• Sanofi S.A.
• GSK plc
• Eli Lilly and Company
• Regeneron Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Limited
• Biogen Inc.
• UCB S.A.
• Astellas Pharma Inc.
• Bayer AG
• Sandoz International GmbH

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us